Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

A Multifaceted Intervention Designed to Improve Medical Management of Moderate to Advanced Chronic Kidney Disease in HIV-Infected Patients: A Cluster Randomized Trial.

Abgrall S, Rachas A, Tourret J, Isnard-Bagnis C, Billaud E, Tattevin P, Costagliola D, Guiguet M, Durieux P; French Hospital Database on HIV.

Clin Infect Dis. 2015 Apr 22. pii: civ310. [Epub ahead of print]

PMID:
25904366
2.

Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.

de Monteynard LA, Dray-Spira R, de Truchis P, Grabar S, Launay O, Meynard JL, Khuong-Josses MA, Gilquin J, Rey D, Simon A, Pavie J, Mahamat A, Matheron S, Costagliola D, Abgrall S; French Hospital Database on HIV.

PLoS One. 2015 Mar 3;10(3):e0118492. doi: 10.1371/journal.pone.0118492. eCollection 2015.

3.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

PMID:
25567330
4.

Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access.

Delaugerre C, Ghosn J, Lacombe JM, Pialoux G, Cuzin L, Launay O, Menard A, de Truchis P, Costagliola D; FHDH-ANRS CO4.

Clin Infect Dis. 2015 Feb 1;60(3):463-72. doi: 10.1093/cid/ciu834. Epub 2014 Oct 23.

PMID:
25344539
5.

Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.

Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4).

AIDS. 2014 Sep 10;28(14):2109-18. doi: 10.1097/QAD.0000000000000382.

PMID:
25265077
6.

Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).

Mary-Krause M, Grabar S, Lièvre L, Abgrall S, Billaud E, Boué F, Boyer L, Cabié A, Cotte L, De Truchis P, Duval X, Duvivier C, Enel P, Gasnault J, Gaud C, Gilquin J, Guiguet M, Katlama C, Khuong-Josses MA, Lacombe JM, Lang S, Lascaux AS, Launay O, Mahamat A, Matheron S, Meynard JL, Pavie J, Pilorgé F, Piroth L, Poizot-Martin I, Potard V, Pradier C, Reynes J, Rouveix E, Selinger-Leneman H, Simon A, Tattevin P, Tissot-Dupont H, Viard JP, Viget N, Costagliola D.

Int J Epidemiol. 2014 Oct;43(5):1425-36. doi: 10.1093/ije/dyu002. Epub 2014 Feb 17.

PMID:
24550249
7.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).

Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12.

8.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

9.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

10.

Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.

Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4.

J Antimicrob Chemother. 2011 Aug;66(8):1869-77. doi: 10.1093/jac/dkr208. Epub 2011 Jun 1.

11.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

12.

Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score.

Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J; FHDH-ANRS CO4.

Neurology. 2011 Feb 15;76(7):644-51. doi: 10.1212/WNL.0b013e31820c3089. Epub 2011 Jan 19.

PMID:
21248274
13.

IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.

Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4; ANRS CO14.

J Antimicrob Chemother. 2010 Oct;65(10):2215-23. doi: 10.1093/jac/dkq296. Epub 2010 Aug 11.

14.

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197.

PMID:
20660842
15.

HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years.

Abgrall S, Del Giudice P, Melica G, Costagliola D; FHDH-ANRS CO4.

AIDS. 2010 Mar 13;24(5):763-71. doi: 10.1097/QAD.0b013e3283366747.

PMID:
20087155
16.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

17.

Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.

Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S; FHDH-ANRS CO4 Clinical Epidemiology Group.

AIDS. 2009 Sep 24;23(15):1997-2004. doi: 10.1097/QAD.0b013e32832f4215.

PMID:
19654499
18.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

19.

How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates.

Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D; Clinical Epidemiologic Group of the French Hospital Database on HIV (ANRS CO4 FHDH); Groupe d'Etude Mortalité 2000.

HIV Med. 2009 Apr;10(4):236-45. doi: 10.1111/j.1468-1293.2008.00678.x. Epub 2008 Jan 28.

PMID:
19178591
20.

Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.

Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):206-14. doi: 10.1097/QAI.0b013e318190018c.

PMID:
19131886
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk